DNA Chip Based Prognosis of Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00973427

Enrollment

144

Registered

2009-09-09

Start date

2008-06-30

Completion date

2014-09-30

Last updated

2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

NSCLC

Brief summary

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. A histological diagnosis of primary NSCLC stage Ia 2. Surgical removal of the tumor 3. Age between 18 and 75 years 4. Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery. 2. Adjuvant treatment with chemotherapy. 3. Prior history of cancer in the past 5 years or breast cancer at any time. 4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Design outcomes

Primary

Measure	Time frame
Disease-related survival	5 years

Secondary

Measure	Time frame
Time to progression	5 years

Countries

Denmark, United States

Outcome results